ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.055,50
-0,65%
S&P 500
6.067,70
0,92%
US Dollar vs BRL
5,8576
-0,62%
Bitcoin
101.161,16
-0,89%
Brent Oil
76,61
0,45%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Oncocyte Corporation (OCX)

  7. Oncocyte Corporation (OCX) Notícias

OCX

Oncocyte (OCX)

Oncocyte Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCX
DataHoraFonteTítuloCódigoCompanhia
08/01/202518:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCXOncocyte Corporation
08/01/202510:30GlobeNewswire Inc.Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerNASDAQ:OCXOncocyte Corporation
06/01/202518:05GlobeNewswire Inc.Oncocyte Expands Market Opportunity for VitaGraft™ KidneyNASDAQ:OCXOncocyte Corporation
09/12/202418:05GlobeNewswire Inc.Oncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsNASDAQ:OCXOncocyte Corporation
09/12/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCXOncocyte Corporation
04/12/202418:15GlobeNewswire Inc.Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyNASDAQ:OCXOncocyte Corporation
02/12/202418:05GlobeNewswire Inc.Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms NASDAQ:OCXOncocyte Corporation
12/11/202418:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCXOncocyte Corporation
12/11/202418:05GlobeNewswire Inc.Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025NASDAQ:OCXOncocyte Corporation
06/11/202418:45GlobeNewswire Inc.Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12NASDAQ:OCXOncocyte Corporation
22/10/202417:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCXOncocyte Corporation
22/10/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCXOncocyte Corporation
18/10/202417:55Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:OCXOncocyte Corporation
16/10/202418:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OCXOncocyte Corporation
16/10/202417:15GlobeNewswire Inc.Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesNASDAQ:OCXOncocyte Corporation
08/10/202417:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:OCXOncocyte Corporation
08/10/202409:30GlobeNewswire Inc.Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialNASDAQ:OCXOncocyte Corporation
02/10/202419:41GlobeNewswire Inc.Oncocyte Signs Leading Transplant Centers in US and GermanyNASDAQ:OCXOncocyte Corporation
02/10/202419:35GlobeNewswire Inc.Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:OCXOncocyte Corporation
25/09/202417:09Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCXOncocyte Corporation
20/08/202410:00GlobeNewswire Inc.PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyNASDAQ:OCXOncocyte Corporation
12/08/202417:10GlobeNewswire Inc.Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyNASDAQ:OCXOncocyte Corporation
09/08/202407:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCXOncocyte Corporation
08/08/202417:05GlobeNewswire Inc.Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 ResultsNASDAQ:OCXOncocyte Corporation
05/08/202417:05GlobeNewswire Inc.Oncocyte Announces August Investor Conferences ParticipationNASDAQ:OCXOncocyte Corporation
01/08/202417:05GlobeNewswire Inc.Oncocyte to Announce Second Quarter 2024 Financial Results on August 8NASDAQ:OCXOncocyte Corporation
11/07/202409:00GlobeNewswire Inc.MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" EpisodeNASDAQ:OCXOncocyte Corporation
24/06/202413:41GlobeNewswire Inc.Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership MoveNASDAQ:OCXOncocyte Corporation
17/06/202417:05GlobeNewswire Inc.Oncocyte Appoints Andrea James as Chief Financial OfficerNASDAQ:OCXOncocyte Corporation
03/06/202415:13GlobeNewswire Inc.Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft StudyNASDAQ:OCXOncocyte Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RCSL4
RECRUSUL PN
BOV
COGN3
COGNA ON
BOV
HBOR3
HELBOR ON
BOV
FICT3
Fictor Alimentos ON
BOV
GFSA3
GAFISA ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
TELB4
TELEBRAS PN
BOV
PRIO3
PETRORIO ON
BOV
BRAV3
Brava Energia ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMOB3
Automob Participacoes ON
BOV
RAIZ4
Raizen S.A PN
BOV
VVEO3
CM Hospitalar ON
BOV
BOBR4
BOMBRIL PN
BOV
AZEV4
AZEVEDO PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados